Document is current
Any future updates will be listed below
-
Authors
Janssen Daalen, Jules M.
Meinders, Marjan J.
Straatsma, Isabel R.
Ainslie, Philip N.
Thijssen, Dick H. J.
Bloem, Bastiaan R.
-
Funding
Funding for this research was provided by:
Michael J. Fox Foundation for Parkinson's Research (019201, 019201, 019201, 019201)
- License Information
-
More Information
Article History
Received: 8 May 2023
Accepted: 7 June 2023
First Online: 19 June 2023
Declarations
:
: The study is performed according to the 2013 ‘Declaration of Helsinki’ and ‘<i>the Medical Research Involving Human Subjects Act</i> (WMO)’ of the Civil Code of the Netherlands. This study has been approved by the Medical Research Ethics Committee East Netherlands, The Netherlands, (reference number NL.77891.091.22) and has been registered at clinicaltrials.gov (ClinicalTrials.gov Identifier: NCT05214287). Participants are covered by trial insurance issued specifically for this study by Radboud University Medical Center.
: The authors declare no competing interests.
: Bastiaan R. Bloem has received honoraria from serving on the scientific advisory board for Abbvie, Biogen, UCB, and Walk with Path; has received fees for speaking at conferences from AbbVie, Zambon, Roche, GE Healthcare, and Bial; and has received research support from The Netherlands Organisation for Scientific Research, the Michael J. Fox Foundation, UCB, Abbvie, the Stichting Parkinson Fonds, the Hersenstichting Nederland, the Parkinson Foundation, Verily Life Sciences, Horizon 2020, the Topsector Life Sciences and Health, and the Parkinson Vereniging. The other authors have nothing to disclose.
